Scope
Clinical Leukemia is a peer-reviewed quarterly journal that publishes original articles describing various aspects of clinical and translational research of leukemia. Clinical Leukemia is be devoted to articles on the detection, diagnosis, prevention, and treatment of leukemia. The main emphasis is on recent scientific developments in all areas related to leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

Editorial Policies
Submitted manuscripts should be original articles of high quality. Journal policy requires that authors reveal in a letter to the Editors-in-Chief any relationships that could be construed as conflicts of interest with regard to the manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

The Publisher endorses the principles embodied in the Declaration of Helsinki and expects that all investigations involving human subjects were performed in accordance with these principles. The investigators’ institutional review board must have approved all human studies..

The manuscript cover letter must state that all persons listed as authors have contributed to the stuady and in preparing the manuscript. Authors will be asked to transfer copyright of articles accepted for publication to CIG Media Group, LP.

Manuscript Preparation

Style
Articles should be written clearly and concisely. The manuscript must be typed and double-spaced. Fonts should be 10 points or larger; margins should be 1 inch all around. Number pages consecutively beginning with the title page. All copies must contain a complete set of tables, figures, and legends. Submit article electronically at www.cigjournals.com.

Title page
All types of manuscripts require a title page. Provide an appropriate title describing the subject matter of the manuscript. List the first names, middle initials, and last names of authors with their department and institutional affiliations. Provide the name, complete mailing address, phone/fax number, and e-mail address of the corresponding author. Provide an abbreviated title of ≤ 100 characters. Provide 4-6 simple key words. These should be words that do not appear in the title. Do not use abbreviations or commercial names in the title or the abbreviated title.

Abstract
Provide an unstructured abstract of no more than 250 words on a separate page. Original contribution articles should contain a structured abstract.

Text
The body of the manuscript should be divided into 6 parts:
Introduction. Start on a new page. Indicate why the topic is important and state the specific objective(s) of the study. The length should not exceed 1-2 pages.

Patients and Methods or Material and Methods. Describe the methods, equipment, and techniques used as well as details of the protocols. Add a paragraph to describe the statistical methods used. The length should not exceed 1-3 pages.

Results. Describe succinctly the results obtained. Describe how observations across studies were tabulated and integrated. The length should not exceed 2-4 pages.

Discussion. The discussion should focus on the findings of the current work. When applicable, the discussion may also include a comparison of the results to those found in similar studies. The length should not exceed 2-4 pages.

Conclusion. The conclusion should summarize the findings from the current study, including clinical implications and the need for additional research. The length should not exceed 1-2 pages.

Figures, Tables, and Legends. Lettering and identifying marks must be clear, sharp, and large enough to see when published. All figures must have a resolution of at least 300 dpi. Identify the critical area(s) of x-rays, MRIs, PETs, SPECTs, CTs, and photomicrographs. Type all legends on a separate page, not on the figure itself, and define any abbreviations in the figure. For tables, footnotes may be used if needed, all abbreviations used should be defined, and sufficient information must be included to make the table self-explanatory. Do not use a table for data that can be described adequately in 2-3 sentences in the text. If a previously published figure or table is to be used, a letter of permission from the copyright holder must be provided by the corresponding author upon acceptance of the manuscript.

References
Authors are responsible for the accuracy of all references. The format must adhere to the specifications of the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” promulgated by the International Committee of Medical Journal Editors (N Engl J Med 1997; 336:309-315). Examples of specific types of references are listed below. References are numbered consecutively in the order they appear in the text. References appearing for the first time in a table or figure should be cited in the text where the table or figure is mentioned. Citations are in superscript. Each reference must be cited. Journal names should be abbreviated according to the style of Index Medicus, National Library of Medicine.

Please note that no periods are used after the authors’ initials or after journal abbreviations given in the reference list; “et al” is used when there are more than 3 authors. There is a period at the end of each reference. Abstracts must include the volume, page, and abstract numbers.

Manuscript Review
Manuscripts are screened for completeness. Receipt of the manuscript is acknowledged. All manuscripts are subjected to peer review, typically 2 in number. Usually one of the reviewers is a member of the Editorial Board and the other is an outside expert chosen for his/her knowledge and scope of the subject matter of the manuscript.

Authors may suggest the name of a specific reviewer whom they believe to be particularly qualified to review the manuscript. If you do not wish to have your manuscript reviewed by a particular reviewer, you may state so. All such requests are regarded as confidential and will be considered by the Editors-in-Chief when assigning reviewers.

Accepted Manuscripts
Upon acceptance for publication, the manuscript is copyedited. The galley proofs of the manuscript are sent to the corresponding author for final review. The authors must check proofs carefully and make only necessary changes. The author should return the galley proofs to the publisher via fax or overnight mail within 24- 48 hours as requested.

Types of Articles
Comprehensive Review
Review articles collate, describe, and evaluate prior publications of important clinical subjects related to leukemia, accompanied by critical analysis leading to rational conclusions. Reviews range in length from 2000 to 5000 words. Title page, abstract, abbreviated title, and key words are necessary.

Original Contribution
These articles present results of original clinical research that is important and relevant to leukemia. Clinical investigations range in length from 2000 to 4000 words. Title page, abstract, abbreviated title, and key words are necessary. The abstract must be structured.

Case Reports
Case reports of educational value are of interest. They may describe a single case or a small series of cases. Case reports that draw attention to important clinical situations, unusual clinical phenomena, new treatment protocols, or new complications are needed. Case reports range in length from 500 to 1500 words. Title page, abstract, abbreviated title, and key words are necessary.

Current Trials
Current trials of educational value are invited for inclusion. They describe the rationale, criteria, treatment plan, and anticipated results. They may describe a small series of cases. Current trials range in length from 500 to 1500 words. Title page, abbreviated title, and key words are necessary.

Translational Medicine
Articles that deal with basic research with clinical application are invited for inclusion. A description of development of basic research with presentation of basic research data as well as data obtained from human samples or patients are necessary. A discussion of how this translation approach impacts the treatment of leukemia patients is essential. Length could vary from 3000 to 5000 words. Title page, abstract, abbreviated title, and key words are necessary.

Imaging in Breast Cancer
Articles that deal with novel diagnostic imaging techniques (eg, MRI, CT, PET, SPECT, and others) are invited for inclusion. Articles on modalities for diagnostic purposes, on outcome according to the pathologic grade or to monitor distant lesions are of interest to the readership. Articles submitted may describe individual cases (1500-2000 words) or series of cases (2000-3000 words). Title page, abstract, abbreviated title, and key words are necessary.

Clinical Concepts and Commentary
These invited articles are brief reviews and commentaries (1000-2500 words) focused on clinical topics that are novel or controversial and require rapid dissemination. A title page and an abbreviated title are needed.

Letter to the Editor
These articles should be brief (250-500 words). A few references, a small table, or a pertinent illustration may be used. A title page and an abbreviated title are necessary.

Brief Communication
These are brief articles (500-1500 words) with a maximum of 2 tables and 2 figures. Title page, abstract, abbreviated title, and key words are necessary.

Other Items
Clinical Leukemia will publish highlights/reports of scientific meetings and book reviews. Please contact the editorial office for further information.

Submission of Manuscripts
Manuscripts should be submitted electronically at www.cigjournals.com. Click on a specific title and follow the prompts. Manuscripts may be submitted as Microsoft Word files containing text, tables, and figures.

Editors-in-Chief
ClinicalLeukemia, 3500 Maple Avenue, Suite 750, Dallas, TX 75219 USA
Phone: 214-367-3350; Fax: 214-367-3301

Permissions
Lengthy direct quotations, tables, or figures from previously published sources must be accompanied by written permission from the copyright holder. Complete information of the source of the material also must be provided. No part of the materials published in Clinical Leukemia may be reproduced without written permission. If you require assistance with the permission process, please contact the editorial office at 214-367-3348.

If you do not have Adobe Acrobat, you may download it by clicking the banner below